A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Exclusion Criteria

• •1. Pregnancy.
• •2. Hyperparathyroidism, or other granulomatous disease.
• •3. Hepatitis b surface antigen positive.
• •4. Hepatitis c antibody positive, or HIV antibody positive.
• •5. Receiving dialysis for renal failure.
• •6. Known sensitivity to JMT103 composition.
• •7. Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of screening CSC.
• •8. Treatment with cinacalcet within 4 weeks prior to the date of screening CSC.
• •9. Currently participating another clinical study，or Four weeks or less since receiving an investigational product in another clinical study.
• •10. In the opinion of the investigator , being unsuitable for inclusion in the study，or subjects withdraw informed consent.
• •11. Treatment with monoclonal antibody to RANK ligand (RANKL) within 180 days prior to the date of the screening CSC.